Mona Djalali1, Mahmoud Djalali2, Mina Abdolahi2, Hamed Mohammadi3, Hajar Heidari3, Shayesteh Hosseini4, Majid Sadeghizadeh1. 1. Department of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran. 2. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. 3. Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. 4. Faculty of Basic Sciences, Tehran Branch, Islamic Azad University, Tehran, Iran.
Abstract
BACKGROUND: This study was designed to investigate the effect of nano-curcumin supplementation on pentraxin 3 (PTX3) gene exp ression and serum level in migraine patients. METHODS: The present study, performed as a clinical trial, included 38 episodic migraine patients in two groups that received either nano-curcumin or placebo over a two-month period. At the start and the end of the study, PTX3 gene expression and serum levels were measured. RESULTS: After two months of treatment, PTX3 gene expression and serum levels were both significantly less in the nano-curcumin than in the placebo group (P= 0.01 and P< 0.001, respectively). No significant gene expression differences were found between the two groups. CONCLUSION: Curcumin may have a potential inhibitory effect on PTX3 gene expression and serum levels in migraine disease and can be considered as an efficient therapy in migraine management.
BACKGROUND: This study was designed to investigate the effect of nano-curcumin supplementation on pentraxin 3 (PTX3) gene exp ression and serum level in migraine patients. METHODS: The present study, performed as a clinical trial, included 38 episodic migraine patients in two groups that received either nano-curcumin or placebo over a two-month period. At the start and the end of the study, PTX3 gene expression and serum levels were measured. RESULTS: After two months of treatment, PTX3 gene expression and serum levels were both significantly less in the nano-curcumin than in the placebo group (P= 0.01 and P< 0.001, respectively). No significant gene expression differences were found between the two groups. CONCLUSION: Curcumin may have a potential inhibitory effect on PTX3 gene expression and serum levels in migraine disease and can be considered as an efficient therapy in migraine management.
Authors: Elles J Mulder; Caroline Van Baal; David Gaist; Mikko Kallela; Jaakko Kaprio; Dan A Svensson; Dale R Nyholt; Nicholas G Martin; Alex J MacGregor; Lynn F Cherkas; Dorret I Boomsma; Aarno Palotie Journal: Twin Res Date: 2003-10